Freenome

Freenome is a biotechnology company on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases.

By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238 million from investors such as RA Capital, Polaris Partners, Perceptive Advisors, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, and Verily Life Sciences (formerly Google Life Sciences).